| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/08/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 9% stake in SERES THERAPEUTICS, INC. |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
4
| Henn Matthew R. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $10.84, valued at
$379.4k
|
|
| 04/27/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 5% stake in Seres Therapeutics, Inc. |
| 03/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in SERES THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 4.9% stake in Seres Therapeutics Inc. |
| 02/07/2023 |
4
| Ege David S. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,500 restricted stock units
@ $0
Granted 95,000 options to buy
@ $5.5, valued at
$522.5k
|
|
| 02/07/2023 |
4
| von Moltke Lisa (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,500 restricted stock units
@ $0
Granted 95,000 options to buy
@ $5.5, valued at
$522.5k
|
|
| 02/07/2023 |
4
| Henn Matthew R. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 45,000 restricted stock units
@ $0
Granted 90,000 options to buy
@ $5.5, valued at
$495k
|
|
| 02/07/2023 |
4
| DesRosier Thomas (Chief Legal Officer and EVP) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 42,500 restricted stock units
@ $0
Granted 85,000 options to buy
@ $5.5, valued at
$467.5k
|
|
| 02/07/2023 |
4
| Shaff Eric D. (CEO and President) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 125,000 restricted stock units
@ $0
Granted 250,000 options to buy
@ $5.5, valued at
$1.4M
|
|
| 02/07/2023 |
4
| Arkowitz David (CFO) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 42,500 restricted stock units
@ $0
Granted 85,000 options to buy
@ $5.5, valued at
$467.5k
|
|
| 02/07/2023 |
4
| Young Teresa L. (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 42,500 restricted stock units
@ $0
Granted 85,000 restricted stock units
@ $0
Granted 85,000 options to buy
@ $5.5, valued at
$467.5k
|
|
| 02/07/2023 |
4
| Cloghessy Paula (See Remarks) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 47,500 restricted stock units
@ $0
Granted 95,000 options to buy
@ $5.5, valued at
$522.5k
|
|
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.2% stake in Seres Therapeutics, Inc. |
| 02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 14.5% stake in SERES THERAPEUTICS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
|